Short answer · Medically reviewed summary · Last updated: 2026-05-08
The primary treatment for Hemimegalencephaly involves managing refractory seizures, often requiring a combination of anti-seizure medications and, frequently, neurosurgical intervention such as a functional hemispherectomy. Because Hemimegalencephaly involves the overgrowth of one cerebral hemisphere, treatment must be highly personalized based on the severity of neurological impairment and seizure frequency. What are the primary medical treatments for Hemimegalencephaly? Treatment for Hemimegalencephaly typically begins with anti-seizure medications (ASMs) to control epilepsy, which affects the vast majority of patients.
The primary treatment for Hemimegalencephaly involves managing refractory seizures, often requiring a combination of anti-seizure medications and, frequently, neurosurgical intervention such as a functional hemispherectomy. Because Hemimegalencephaly involves the overgrowth of one cerebral hemisphere, treatment must be highly personalized based on the severity of neurological impairment and seizure frequency.
Treatment for Hemimegalencephaly typically begins with anti-seizure medications (ASMs) to control epilepsy, which affects the vast majority of patients. Commonly prescribed medications include levetiracetam (Keppra), oxcarbazepine (Trileptal), or vigabatrin (Sabril). However, because Hemimegalencephaly is often medically refractory, meaning it does not respond well to drugs alone, surgery is frequently the definitive treatment. A functional hemispherectomy or hemispherotomy is often performed to disconnect the affected, overdeveloped hemisphere from the healthy brain tissue to stop seizure propagation.
Beyond surgery and medication, a multidisciplinary approach is essential for managing the developmental impact of Hemimegalencephaly. Comprehensive care plans often include:
Managing Hemimegalencephaly requires a specialized team. Key providers include a pediatric neurologist, an epileptologist, a neurosurgeon specializing in pediatric epilepsy, a geneticist, and physical/occupational therapists. Currently, research into the somatic genetic mutations (such as those in the PIK3CA or AKT3 genes) driving Hemimegalencephaly is expanding, with some clinical trials investigating targeted molecular therapies that may eventually supplement surgical options.
Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; always consult your personal healthcare team for treatment decisions.